SCAD SERVE Community Fund awards $2 million in grants
This initiative is part of SCAD's ongoing 10-million-dollar commitment to strengthening local communities. Recipients include America's Second Harvest of Coastal Georgia and the City of Savannah.
The funding will help expand public safety measures, upgrade technology for workforce training, create a new community space at Greenbriar and launch a mobile grocery store.
Mary Jane Crouch, Executive Director of America's Second Harvest says, 'SCAD's not only going to help us fund the project, they're also going to help us design the truck inside and outside. The interior and exterior. Classes are gonna help us design it. Where should the freezers go? Where should the coolers go? And things like that. I'm sure they'll get involved in helping us find the different locations and then hopefully — their SCAD student's we'll be able to come and volunteer.'
SCAD says this is just the first round of grants with more to come.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
09-05-2025
- Yahoo
New homeless resource center to open in Savannah
SAVANNAH, Ga. (WSAV) – Friday, Union Mission announced its plan for the former Family Dollar building at 702 West Oglethorpe Avenue in Savannah. The announcement included a preview of the space for a new Resource Center focused on solutions for the area's homeless population. Union Mission partnered with the Savannah College of Art and Design (SCAD) to help envision the interior and exterior design of the new 8,200 square foot Resource Center through the university's SCAD SERVE Design for Good course. This course includes students in interior design, architecture, graphic design, illustration, design management and other top-ranked degree programs. 'Our talented junior designers spent 10 weeks developing a unique and inviting space that would feel safe, accessible and welcoming for the unhoused community,' said SCAD SERVE Professor Scott Horner. 'While using industry leading technology along with knowledge and expertise gained from world-leading faculty, the students developed insights and innovations through collaboration and cross-pollination to create a space that not only met but exceeded the needs of the client.' SCAD SERVE Vice President Scott Linzey said, 'For multiple decades SCAD has been dedicated to using university resources to improve lives of citizens in our hometowns. SCAD SERVE Design for Good courses are a perfect manifestation of that as they provide focused innovation and strategic creativity to non-profit organizations who would otherwise not have access to the superior design thinking of SCAD students.' The expansion is the next step Union Mission's successful Day Center at Grace House with services that provide case management, mental health counseling, workforce development, engagement and many other wrap-around services that help the homeless address barriers to employment and housing. 'This expansion will provide space to increase Union Mission's impact,' said Michael Traynor, President & CEO of Union Mission. 'It will help us better collaborate and engage to offer a wide range of our own and partner services, providing holistic support that meets immediate needs and empowers people on their journey to self-sufficiency.' Union Mission opened its Day Center more than 28 months ago and has filled a critical community need. Homelessness was leaving many unhoused individuals with no place to go during the day. In partnership with the City of Savannah and the Chatham Savannah Authority for the Homeless, the Day Center provides support services and warm meals for men and women seeking respite six days a week. While initially planning to serve 50 clients daily, the Day Center now averages 119 per day, with a recent record of 144. Since its inception, the Day Center has served 1,551 individuals with more than 48,000 visits and 120,000 meals. The new Resource Center will include a Day Center, but the current center's growth requires a strategic expansion to increase solutions and better serve the communities dynamic needs. The new Resource Center will offer the following: An expanded Day Center to serve up to 150 attendees each day to include a serving kitchen, dining space, designated private space for nursing services and laundry services to address basic needs. Supportive services and enrichment opportunities to include counseling, support groups, visiting partner services and workforce training and placement. Intake, assessment and housing program navigation with case management, program intake and assessment, connections to benefits and resources and solutions to housing barriers. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
20-02-2025
- Yahoo
SCAD SERVE Community Fund awards $2 million in grants
SAVANNAH, Ga. (WASV) — The Savannah College of Art and Design is making a major investment in its hometown communities. The University has awarded nearly 2 million dollars in grants to nonprofits in Savannah and Atlanta through the SCAD Serve Community Fund. This initiative is part of SCAD's ongoing 10-million-dollar commitment to strengthening local communities. Recipients include America's Second Harvest of Coastal Georgia and the City of Savannah. The funding will help expand public safety measures, upgrade technology for workforce training, create a new community space at Greenbriar and launch a mobile grocery store. Mary Jane Crouch, Executive Director of America's Second Harvest says, 'SCAD's not only going to help us fund the project, they're also going to help us design the truck inside and outside. The interior and exterior. Classes are gonna help us design it. Where should the freezers go? Where should the coolers go? And things like that. I'm sure they'll get involved in helping us find the different locations and then hopefully — their SCAD student's we'll be able to come and volunteer.' SCAD says this is just the first round of grants with more to come. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Associated Press
19-11-2024
- Associated Press
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS
NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siRNA therapy targeting the FUS gene, for the treatment of amyotrophic lateral sclerosis (ALS). RAG-21 is an siRNA therapy specifically designed to target FUS-ALS, one of the most aggressive subtype of ALS. By leveraging RNA interference (RNAi), RAG-21 safely and effectively reduces FUS protein levels, addressing the root cause of motor neuron degeneration in FUS-ALS. Preclinical studies have demonstrated its potent efficacy and safety, mitigating FUS cytoplasmic mis-localization and aggregation. As a novel RNA-based therapy, RAG-21 offers renewed hope for improving outcomes in patients suffering from this challenging form of ALS, which currently lacks effective treatment options. This designation marks our second FDA ODD for treating ALS, following RAG-17 for SOD1-ALS, reflecting our commitment to conquering ALS. Orphan drug designation is granted by the FDA to a drug intended to treat a rare disease or condition, which generally affects fewer than 200,000 individuals in the United States. The designation provides companies with incentives including a 25% tax credit on qualified clinical trials, a seven-year marketing exclusivity and a waiver of the New Drug Application fee. 'The FDA's Orphan Drug Designation for RAG-21 underscores the critical need for innovative therapies targeting ALS, particularly for patients with FUS mutations,' said Dr. Long-Cheng Li, Founder and CEO of Ractigen Therapeutics. 'FUS-ALS represents one of the most severe and rapidly progressing subtypes of ALS, with no curative treatments currently available. We are committed to developing innovative therapies like RAG-21 to provide meaningful treatment options for patients with ALS and other life-threatening rare diseases.' About RAG-21 RAG-21 utilizes RNA interference to selectively reduce FUS mRNA transcripts. This mechanism prevents the production of toxic FUS proteins and addresses the underlying pathology of FUS-ALS. Delivered via the SCAD™ platform, RAG-21 achieves targeted, efficient, and durable gene knockdown within the CNS. Preclinical data highlight its potential to mitigate motor neuron degeneration and improve disease outcomes, offering hope for patients with this aggressive ALS subtype. About ALS and FUS Mutations ALS is a devastating neurodegenerative disease with no cure, significantly impairing patients' quality of life. Most patients succumb to respiratory failure within 2-5 years of diagnosis. Mutations in the FUS gene are associated with a particularly aggressive form of ALS, characterized by early onset and rapid progression. These mutations lead to toxic protein accumulation, mis-localization, and the formation of abnormal inclusions in neurons, ultimately lead to motor neuron degeneration. Despite progress in ALS drug development, effective treatments remain elusive, especially for FUS-ALS. Current therapies, such as Riluzole and Edaravone, offer only modest benefits and are not specific to FUS-ALS. RNA-based therapeutics, including siRNA, represent a promising strategy by directly targeting disease-driving genes like FUS to address the root cause of the disease. About Ractigen Therapeutics A leader in small activating RNA (saRNA) drug development, Ractigen Therapeutics is at the forefront of developing saRNA drugs utilizing RNA activation (RNAa) mechanism to up-regulate endogenous gene expression. This innovative approach involves saRNA targeting specific genes to enhance transcription, thereby restoring normal protein functions. Ractigen's cutting-edge technology is pivotal in treating diseases unaddressable by conventional methods, such as those resulting from epigenetic silencing or gene downregulation. For more information, please visit our website at
